Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone
about
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation.Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioDonor bone marrow-derived T cells inhibit GVHD induced by donor lymphocyte infusion in established mixed allogeneic hematopoietic chimeras.HDAC inhibition and graft versus host diseaseA phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantationRegulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.Nonalloreactive T cells prevent donor lymphocyte infusion-induced graft-versus-host disease by controlling microbial stimuli.Cellular therapy following allogeneic stem-cell transplantation.Graft-versus-host disease after donor leukocyte infusions: presentation and management.Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity.Modeling Human Leukemia Immunotherapy in Humanized MiceDonor lymphocyte infusions: the long and winding road: how should it be traveled?New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.New perspectives on the biology of acute GVHD.Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.Role of natural killer cells in hematopoietic stem cell transplantation: myth or reality?Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Clinical relevance of natural killer cells following hematopoietic stem cell transplantation.Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation.Hematopoietic stem cell transplantation and cellular therapy.Keratinocyte growth factor enhanced immune reconstitution in murine allogeneic umbilical cord blood cell transplant.Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature.Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study.Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant.Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant.
P2860
Q33685495-13B3FC94-07AA-47B2-AE24-365AB4CFF944Q33770125-204D0B88-2918-4D24-92A1-CC6A41B7A4AEQ33937048-EC51C767-2B37-46A4-AA80-FC1854DB7978Q34065058-74FA7E60-580D-4691-8068-1FE0EA60E54BQ34202277-0A9B035E-2388-4406-BE9C-39ABB92C4921Q34450566-EF0ACF72-630B-475E-9342-1FF764F1F266Q35016985-97EF80F6-F21F-4B1D-B0A6-36FBBE2D1FE1Q35068749-96B0385C-902F-41A2-973F-2797E2B29C9EQ35553553-7444D137-74D0-44AF-B86D-1F974D8691B6Q36062047-63D8EF70-6891-456A-8E4D-2E2BCEE367A7Q36474155-367CBECF-47A9-4C81-B1B1-01867479B9F8Q36612643-D060BB4F-ACCA-4D6F-80BD-0F1869BE5F27Q36825001-B2CB8E7E-1540-4BD2-98BD-358507AED39DQ37061964-0A460A60-A4FA-4F63-B1E4-844E12D4010DQ37209082-4511799E-A28A-45DF-9731-B6D2B06342E6Q37221363-C991EDD4-5DE9-4739-B120-75EC99FABDDAQ37246638-A6007C37-0551-4D90-A73B-990CC475F618Q37344050-958CEB0E-05B3-48AE-ACFA-68FEAF1BFC69Q37641063-014187F7-E1D0-4D45-AFD2-3AEE031FDC50Q37822742-D8A1CB5D-0056-44E1-8A39-1C395B97BD26Q37853787-BC23213B-BA25-421A-8E0D-0A791F4589CBQ37905034-B253DE75-E9E0-4E14-99D4-B0B4D0E0519BQ38079585-3781B8D2-7A1C-4C59-A496-45F9AC083F36Q38219579-F999B342-753E-433D-98F3-8E50D73CDFFEQ38643400-D0C6D449-75D0-4FF2-B4C2-2A5FD97592BFQ38660984-5DA58AD9-E3E7-44A6-9E5D-7D99112CEDA1Q39216720-9558B9D8-F28F-4E93-817A-BAD17E702E93Q39529193-079FDD94-106D-438E-AF7F-F1FA5C5342AEQ40296180-3361E10D-7FCC-48B2-AF43-D91157E84680Q41336256-7715A702-E88E-4ED4-80FC-C5E7BC2A0A29Q44821593-A54A3324-EACC-40E1-8EBD-93285EE217F6Q50975980-4E67CE8B-7526-4AFE-84FB-F35D4BA5ADFEQ52624498-FE78FF43-A0CE-485F-A24A-B820D2D8F41D
P2860
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Lymphodepletion followed by do ...... us-host disease than DLI alone
@ast
Lymphodepletion followed by do ...... us-host disease than DLI alone
@en
type
label
Lymphodepletion followed by do ...... us-host disease than DLI alone
@ast
Lymphodepletion followed by do ...... us-host disease than DLI alone
@en
prefLabel
Lymphodepletion followed by do ...... us-host disease than DLI alone
@ast
Lymphodepletion followed by do ...... us-host disease than DLI alone
@en
P2093
P2860
P1433
P1476
Lymphodepletion followed by do ...... us-host disease than DLI alone
@en
P2093
Arne Slungaard
Daniel J Weisdorf
Jeffrey S Miller
John E Wagner
Linda J Burns
Michael R Verneris
Roby Nicklow
Rosanna Wangen
Sarah Cooley
Susan K Fautsch
P2860
P304
P356
10.1182/BLOOD-2007-05-090340
P407
P577
2007-06-19T00:00:00Z